USSTOCK.TODAY
Weekend. Closed
Log in Sign up

ESMO 2026: Clinical Data for Pancreatic and Prostate Cancer Treatments Announced

Clinical Trials Arena ·

RVMD Revolution Medicines Inc
$186.99 -0.37%
View chart & analysis →
  1. 1The median overall survival for patients treated with Revolution Medicines' Rasonque was 13.2 months, compared to 6.7 months in the standard treatment group.
  2. 2Among ABBV-969 Phase 1 clinical trial patients, 90% recorded at least a 50% reduction in ctDNA through cycle 3.
  3. 3Tango Therapeutics plans to initiate a pivotal Phase 3 clinical trial in the first half of 2027.

So what's the key point?

Revolution Medicines' drug extended patient survival to 13.2 months compared to existing treatments. This result is positive news for the related companies.

Source Clinical Trials Arena · View original ↗

Related 3-line summaries

Moderna shares plunge nearly 20% following cancer vaccine data leak Investor's Business Daily +19 · 2d agoVerastem Oncology shares surge 18% following release of early cancer treatment data Barrons.com +1 · Oct 15Revolution Medicine Shares Fall 6% and Zealand Pharma Announces Clinical Results BioPharma Dive · Oct 10
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news